Advertisement

Topics

U.S. FDA outlines plan to speed rare disease drug reviews

07:05 EDT 29 Jun 2017 | Reuters

WASHINGTON (Reuters) - The U.S. Food and Drug Administration plans to reorganize its drug review staff and create a SWAT team to eliminate a backlog of drugs for rare diseases and speed reviews of future applications, it said on Thursday.

Original Article: U.S. FDA outlines plan to speed rare disease drug reviews

NEXT ARTICLE

More From BioPortfolio on "U.S. FDA outlines plan to speed rare disease drug reviews"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...